Article
Oncology
Enora Laas, Julie Labrosse, Anne-Sophie Hamy, Gabriel Benchimol, Diane de Croze, Jean-Guillaume Feron, Florence Coussy, Thomas Balezeau, Julien Guerin, Marick Lae, Jean-Yves Pierga, Fabien Reyal
Summary: The study compared the prognostic performance of Residual Cancer Burden (RCB) and Neo-Bioscore in different subtypes of breast cancer, finding that RCB had better prognostic performance in various subtypes. In the global population, both RCB and Neo-Bioscore were associated with disease-free and overall survival, but RCB had lower concordance index values.
BRITISH JOURNAL OF CANCER
(2021)
Article
Chemistry, Analytical
Shadi Momtahen, Maryam Momtahen, Ramani Ramaseshan, Farid Golnaraghi
Summary: This study introduced a machine-learning-based optical biosensor called the Opti-scan probe to assess residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). The machine learning model achieved a high accuracy of 0.98 in predicting RCB number/class based on the changes in optical properties measured by the Opti-scan probe. These findings suggest that the ML-based Opti-scan probe has considerable potential as a valuable tool for the assessment of breast cancer response after NAC and to guide treatment decisions.
Article
Oncology
M. Marczyk, A. Mrukwa, C. Yau, D. Wolf, Y-Y Chen, R. Balassanian, R. Nanda, B. A. Parker, G. Krings, H. Sattar, J. C. Zeck, K. S. Albain, J. C. Boughey, M. C. Liu, A. D. Elias, A. S. Clark, S. J. Venters, S. Shad, A. Basu, S. M. Asare, M. Buxton, A. L. Asare, H. S. Rugo, J. Perlmutter, A. M. DeMichele, D. Yee, D. A. Berry, L. van't Veer, W. F. Symmans, L. Esserman, L. Pusztai
Summary: This study developed a new method to quantify the cytotoxic efficacy of treatments by comparing the entire distribution of residual cancer burden (RCB) values between clinical trial arms. The method, called the Treatment Efficacy Score (TES), was found to be a better early surrogate for predicting trial arm level survival differences than the difference in pathologic complete response (pCR) rate alone.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Ji-Yeon Kim, Jung Min Oh, Se Kyung Lee, Jonghan Yu, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Yeon Hee Park, Jin Seok Ahn, Kyunga Kim, Young-Hyuck Im
Summary: A model combining postoperative Ki-67 value and residual cancer burden (RCB) was developed to improve survival outcome prediction for breast cancer patients who underwent neoadjuvant chemotherapy. The model showed superior predictive value for disease-free survival (DFS) and overall survival (OS) compared to the RCB model.
FRONTIERS IN ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sadia Choudhery, Daniel Gomez-Cardona, Christopher P. Favazza, Tanya L. Hoskin, Tufia C. Haddad, Matthew P. Goetz, Judy C. Boughey
Summary: This study extracted volumetric pretreatment MRI radiomics features in breast cancer patients and found that these features were associated with different molecular subtypes, pathological complete response, and residual cancer burden.
ACADEMIC RADIOLOGY
(2022)
Article
Oncology
N. Hou, J. Wu, J. Xiao, Z. Wang, Z. Song, Z. Ke, R. Wang, M. Wei, M. Xu, J. Wei, X. Qian, X. Xu, J. Yi, T. Wang, J. Zhang, N. Li, J. Fan, G. Hou, Y. Wang, Z. Wang, R. Ling
Summary: An excellent prognostic model for predicting disease-free survival in breast cancer patients receiving neoadjuvant chemotherapy was established and demonstrated to outperform other available models. Risk stratification based on the model can help determine recurrence risk levels, tailor personalized intensive treatments, and select comparable study cohorts for clinical trials.
Article
Oncology
Henry M. Kuerer, Benjamin D. Smith, Savitri Krishnamurthy, Wei T. Yang, Vicente Valero, Yu Shen, Heather Lin, Anthony Lucci, Judy C. Boughey, Richard L. White, Emilia J. Diego, Gaiane M. Rauch
Summary: This study aims to evaluate whether radiotherapy alone can replace breast surgery in early-stage triple-negative breast cancer or HER2-positive breast cancer patients who have achieved pathological complete response through image-guided vacuum-assisted core biopsy.
Article
Cell Biology
Dawn Harter, Siobhan M. O'Connor, Johann D. Hertel, Benjamin C. Calhoun
Summary: What is excluded from the measurement of residual tumor after neoadjuvant chemotherapy for breast cancer in the 8th edition of the AJCC Staging System was examined. It was found that strict adherence to the yAJCC criteria resulted in downstaging of tumors and changes in tumor characteristics. The downstaging was associated with tumor subtype and histological pattern of response.
Article
Surgery
Wei Wang, Yinhua Liu, Hong Zhang, Shuang Zhang, Xuening Duan, Jingming Ye, Ling Xu, Jianxin Zhao, Yuanjia Cheng, Qian Liu
Summary: The study retrospectively analyzed clinicopathological data of patients treated between January 1, 2010 and December 31, 2018, finding that RCB index and the Miller-Payne system were associated with prognosis in the whole cohort, with RCB showing superior prediction accuracy, especially for triple-negative breast cancer (TNBC) patients. New cut-off values should be explored to enhance prediction accuracy.
Article
Oncology
Vivian Koelbel, Andre Pfob, Benedikt Schaefgen, Peter Sinn, Manuel Feisst, Michael Golatta, Christina Gomez, Anne Stieber, Paul Bach, Geraldine Rauch, Joerg Heil
Summary: By analyzing data from a prospective multicenter trial, it was found that the presence of accompanying ductal carcinoma in situ (DCIS), multicentric disease on imaging before NST, and age were key characteristics associated with false-negative vacuum-assisted biopsy (VAB) results. Performing a clear representative VAB procedure for patients without accompanying DCIS or multicentric disease may reliably exclude residual cancer in the breast without the need for surgery, reducing the false-negative rate.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Cristian Nicolae Popa, Rodica Daniela Birla, Daniela Elena Dinu, Cristina Iosif, Evelina Bogaseriu, Ioan Nicolae Mates
Summary: This study analyzed the pathological response to chemotherapy in breast cancer patients and found that some patients showed significant tumor shrinkage or complete elimination, suggesting the possibility of conservative surgery. However, certain subtypes of breast cancer had poor response to chemotherapy, and some malignant cells had intrinsic resistance to taxane therapy.
Article
Biochemistry & Molecular Biology
Shriya Joshi, Chakravarthy Garlapati, Shristi Bhattarai, Yixin Su, Leslimar Rios-Colon, Gagan Deep, Mylin A. Torres, Ritu Aneja
Summary: This study evaluated the ability of plasma exosomal metabolic profiles to predict neoadjuvant chemotherapy (NAC) response in breast cancer patients. The results showed that the concentration of exosomes and enrichment of specific metabolic pathways were associated with different treatment outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
H. A. Parsons, T. Blewett, X. Chu, S. Sridhar, K. Santos, K. Xiong, V. G. Abramson, A. Patel, J. Cheng, A. Brufsky, J. Rhoades, J. Force, R. Liu, T. A. Traina, L. A. Carey, M. F. Rimawi, K. D. Miller, V. Stearns, J. Specht, C. Falkson, H. J. Burstein, A. C. Wolff, E. P. Winer, N. Tayob, I. E. Krop, G. M. Markrigiorgos, T. R. Golub, E. L. Mayer, V. A. Adalsteinsson
Summary: This study examined the association between circulating tumor DNA (ctDNA) and residual cancer burden (RCB) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy. The results showed that ctDNA positivity decreased during the course of therapy, and ctDNA clearance at week 12 correlated with RCB status. ctDNA may serve as a potential biomarker for predicting treatment response and prognosis in TNBC patients.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Leisha C. Elmore, Henry M. Kuerer, Carlos H. Barcenas, Benjamin D. Smith, Makesha Miggins, Anthony Lucci, Abigail S. Caudle, Funda Meric-Bernstam, Kelly K. Hunt, Mediget Teshome
Summary: For breast cancer patients receiving NST and experiencing disease progression, the study found a high proportion of patients died and developed distant metastasis. Triple-negative breast cancer patients had a higher risk of death. Despite surgical management, survival rates were still poor.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Jieon Go, Jee Hyun Ahn, Jung Min Park, Soon Bo Choi, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Byeong-Woo Park, Seho Park
Summary: This study evaluated the impact of residual disease on patient prognosis after neoadjuvant chemotherapy (NAC) and analyzed subpopulations with different prognoses. The results showed that there was no significant difference in event-free survival and overall survival between the minimal residual disease (MRD) group and the pathological complete response (pCR) group, except for the triple-negative breast cancer subtype. Therefore, patients with MRD may be considered for de-escalation of post-NAC treatment.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
David Entenberg, Maja H. Oktay, Timothy D'Alfonso, Paula S. Ginter, Brian D. Robinson, Xiaonan Xue, Thomas E. Rohan, Joseph A. Sparano, Joan G. Jones, John S. Condeelis
Article
Oncology
Joseph A. Sparano, Michael R. Crager, Gong Tang, Robert J. Gray, Salomon M. Stemmer, Steven Shak
Summary: A new tool, RSClin, was developed to integrate genomic and clinical features to provide more individualized information for guiding adjuvant chemotherapy in node-negative breast cancer. External validation showed that the RSClin risk estimate was prognostic for distant recurrence risk and closely approximated the observed risk. The integration of clinical-pathological and genomic risk in RSClin offers more precise guidance for adjuvant chemotherapy compared to using clinical-pathological or genomic data alone.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Della Makower, Juan Lin, Xiaonan Xue, Joseph A. Sparano
Summary: The study found a correlation between lymphovascular invasion (LVI) and Black race with poorer prognosis in early breast cancer, but the prognostic impact of LVI varies depending on the disease status. While LVI was associated with worse overall survival in some patients, Black race was linked to poorer overall survival.
Article
Oncology
Gelareh Sadigh, Robert J. Gray, Joseph A. Sparano, Betina Yanez, Sofia F. Garcia, Lava R. Timsina, George W. Sledge, David Cella, Lynne Wagner, Ruth C. Carlos
Summary: This study found that patients with breast cancer who were Medicaid or self-pay and those in the highest quartile of neighborhood deprivation scores were more likely to discontinue endocrine therapy early. These social determinants of health become more important given the rise in unemployment and loss of insurance coverage during the COVID-19 pandemic. Early identification of at-risk patients and enrollment in insurance optimization programs may improve treatment adherence.
Letter
Oncology
Joseph A. Sparano, Michael R. Crager, Gong Tang, Robert J. Gray, Salomon M. Stemmer, Steven Shak
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Olga Kantor, Tari A. King, Steven Shak, Christy A. Russell, Armando E. Giuliano, Gabriel N. Hortobagyi, Harold J. Burstein, Eric P. Winer, Tanujit Dey, Joseph A. Sparano, Elizabeth A. Mittendorf
Summary: The study evaluated the prognostic significance of low-risk recurrence score (RS) in breast cancer patients and explored the potential use of expanded RS criteria for downstaging in AJCC pathologic prognostic staging. The results showed that patients with an RS less than 18 have excellent 5-year disease-specific survival regardless of T category for N0-1 disease, suggesting further modification of AJCC staging system using this cutoff.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Letter
Oncology
Etta D. Pisano, Constantine Gatsonis, Joseph Sparano, Melissa A. Troester, Martin Yaffe, Elodia Cole, Mitchell D. Schnall
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Laura E. Martinez, Shelly Lensing, Di Chang, Larry Magpantay, Ronald Mitsuyasu, Richard F. Ambinder, Joseph A. Sparano, Otoniel Martinez-Maza, Marta Epeldegui
Summary: This study identified that ARL patients who responded well to therapy had lower levels of inflammation and microbial translocation before treatment, as well as several biomarkers significantly decreased after treatment. Additionally, certain biomarkers were associated with overall and progression-free survival in ARL patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Joseph A. Sparano, Anne O'Neill, Noah Graham, Donald W. Northfelt, Chau T. Dang, Antonio C. Wolff, George W. Sledge, Kathy D. Miller
Summary: Systemic inflammation is associated with an increased risk of distant recurrence in breast cancer patients. Higher levels of the proinflammatory cytokine IL-6 at diagnosis are significantly associated with a higher risk of distant recurrence.
Article
Oncology
Della Makower, Jiyue Qin, Juan Lin, Xiaonan Xue, Joseph A. Sparano
Summary: This study examined early ER + HER2- breast cancer patients with different histological subtypes and found that IDC had different clinicopathologic features compared to other cancers and were more likely to receive chemotherapy. Lobular and mixed histologies may have lower recurrence scores, and overall survival rates were similar between IDC and ILC.
Editorial Material
Oncology
Alaina J. Kessler, Joseph A. Sparano
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Letter
Oncology
Seema Ahsan Khan, Fengmin Zhao, Lori Goldstein, Joseph Sparano, George Sledge
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
M. Chadha, J. White, S. M. Swain, E. Rakovitch, R. Jagsi, T. Whelan, J. A. Sparano
Summary: Older women are underrepresented in breast cancer clinical trials, and treatment guidelines are primarily based on studies in younger women. Omission of breast radiation therapy is associated with increased local relapse, but the risk of distant relapse in women aged 70 and above is very low. The incremental benefit of endocrine therapy in decreasing distant relapse rate and improving disease-free survival in older patients with low-risk breast cancer is unclear. Integration of molecular genomic assays in diagnosis and treatment may optimize risk-tailored adjuvant therapies, allowing for treatment de-escalation in older women with early-stage breast cancer. The lack of risk-specific adjuvant therapy guidelines highlights the need for prospective trials to inform optimal treatment selection, including the possibility of omitting adjuvant endocrine therapy in older women with low-risk breast cancer.
Article
Oncology
Jinani Jayasekera, Joseph A. Sparano, Suzanne O'Neill, Young Chandler, Claudine Isaacs, Allison W. Kurian, Lawrence Kushi, Clyde B. Schechter, Jeanne Mandelblatt
Summary: The study developed a flexible clinical decision tool that can assist women with early-stage, node-negative, hormone receptor-positive breast cancer in making more accurate treatment choices.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Gelareh Sadigh, Robert J. Gray, Joseph A. Sparano, Betina Yanez, Sofia F. Garcia, Lava R. Timsina, George W. Sledge, David Cella, Lynne Wagner, Ruth C. Carlos
Summary: The study found that insurance coverage and neighborhood deprivation index at study entry can impact early discontinuation of endocrine therapy in breast cancer patients, with uninsured or underinsured patients more likely to discontinue treatment.